Yellow fever

Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Infectious Disease Solutions

Retrieved on: 
Thursday, October 5, 2023
Yellow fever, Partnership, Infection, Technology transfer, Dengue fever, Collaboration, Government, Kingdom, Betacoronavirus, Entrepreneurship, VIC, Marketing, MENA, GCC, Vaccine, Pharmaceutical industry, Coronavirus

This Collaboration supports the Kingdom of Saudi Arabia’s Vision 2030 to boost the biopharma sector through increasing local and regional production as well as accessibility of healthcare solutions.

Key Points: 
  • This Collaboration supports the Kingdom of Saudi Arabia’s Vision 2030 to boost the biopharma sector through increasing local and regional production as well as accessibility of healthcare solutions.
  • ABINGDON, United Kingdom, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’) a clinical-stage biotechnology company on the forefront of combatting global infectious diseases, has announced that the Company has signed a Memorandum of Understanding with the Vaccine Industrial Company (VIC) for a Collaboration Agreement advancing Emergex’s novel T cell-priming immune set-point candidates against designated infectious diseases.
  • This agreement is a testament to Emergex’s promising technology as a vital contributor to game changing healthcare solutions around the world.
  • Emergex’s novel approach offers a safe, easy-to-administer and highly effective solution, alternative to mainstream methods, to protect against infectious diseases.

Vaccine hesitancy is one of the greatest threats to global health – and the pandemic has made it worse

Retrieved on: 
Tuesday, July 4, 2023
Vaccine, Gaps, MMR, Disease, Vaccination, Parent, Infection, Yellow fever, World Health Organization, Global health, Diphtheria, Research, COVID, Vaccine hesitancy, Government, Measles, Death, Address, Cervical cancer, Cholera, Spectrum, HPV, Misinformation, WHO, World, Safety, Social media, Pharmaceutical industry, UNICEF

In 2019, the World Health Organization (WHO) identified vaccine hesitancy as one of its top ten threats to global health.

Key Points: 
  • In 2019, the World Health Organization (WHO) identified vaccine hesitancy as one of its top ten threats to global health.
  • It appears this threat has only increased since the COVID pandemic.

A perfect storm for infectious diseases

    • In England, for example, childhood vaccination coverage generally plateaued from around 2011 and declined from around 2014.
    • Read more:
      How to dissuade parents from believing in anti-vaxxer conspiracy theories

      Rates of many infectious diseases declined at the height of the pandemic due to widespread social distancing measures, but cases have since started to increase.

    • For example, the number of countries with significant measles outbreaks rose by 50% between 2020–21 and 2022–23.
    • The combination of reduced vaccine coverage, overstretched healthcare systems, and the return to pre-pandemic levels of social contact have created a perfect storm for infectious disease rates to rise.

What drives vaccine hesitancy?

    • One of the main factors leading to hesitancy towards COVID vaccines specifically has been concern that the vaccines were developed too quickly.
    • However, we know that COVID vaccines are safe and effective.

Misinformation is a vector of disease

    • Over the course of the pandemic, we’ve seen widespread misinformation around the safety of COVID vaccines, which has unsurprisingly been linked to reduced confidence in the vaccines.
    • The problem with misinformation is how intractible it can be.

How do we increase vaccine confidence?

    • For example, a study from Japan predicted that vaccine hesitancy in relation to the HPV vaccine between 2013 and 2019 could lead to approximately 5,000 deaths from cervical cancer.
    • Read more:
      Lack of trust in public figures linked to COVID vaccine hesitancy – new research

      To address vaccine hesitancy, we need to tackle the root causes.

    • Crucially, to increase confidence, we need to combat vaccine hesitancy caused by misinformation.
    • Otherwise, vaccine hesitancy will remain one of the greatest threats to global health for years to come.

Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates

Retrieved on: 
Tuesday, June 20, 2023
Vaccine, Fever, Yellow fever, Dengue fever, ANVISA, UKM Medical Molecular Biology Institute, Clinical trial, Research, Ministry, Molecular biology, Death, Ministry of Health (Saudi Arabia), Universal, IBMP, Pharmaceutical industry, Betacoronavirus, Health, Coronavirus, Brazilian, Chikungunya

Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.

Key Points: 
  • Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.
  • Both clinical trial product candidates have successfully completed Phase I+ clinical trials in Switzerland and are nearing submission and evaluation by ANVISA, the Brazilian health regulatory agency.
  • A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialization of the select immunotherapies.
  • IBMP has also made an early equity investment into Emergex, which has potential for future expansion pending the completion of its ongoing due diligence process.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Arbovirus, Gold medal, United States Army Medical Research Institute of Infectious Diseases, Private sector, Sabin Vaccine Institute, Gold, USAMRIID, Vaccination, Virology, Public, Rising Star, Infection, Yellow fever, Smallpox, DRS, Viral, Research, CDC, Fever Dream, Division, Finan, United States Department of the Army, Korea Disease Control and Prevention Agency, Lassa fever, Health, Knowledge, Viral encephalitis, Science, R, System, MPH, Immunization, MD

WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.

Key Points: 
  • WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.
  • Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs.
  • Sabin’s Rising Star is awarded to encourage and recognize the next generation of vaccine and immunization leaders.
  • “With his focus on strengthening immunization and health services among some of our most neglected communities, Dr. Nchinjoh exemplifies the spirit behind the Rising Star award,” says Finan.

Groundbreaking Partnership to Combat Dengue Mosquito in the Republic of the Marshall Islands Will Deploy Oxitec Friendly™ Aedes aegypti Solution

Retrieved on: 
Friday, March 31, 2023
RMI, Male, Partnership, Bee, Human services, Public, Yellow fever, Chikungunya, Centers for Disease Control and Prevention, Female, OXFORD, Government, Butterfly, CDC, Ministry, Notifiable disease, Republic, Fever Dream, Marshall Islands, Stockholm Environment Institute US Center, City, Ecosystem, United States Department of Health and Human Services, Vaccine, Zika fever, Pacific Ocean, Oxitec, Aedes, Ebeye Island

The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.

Key Points: 
  • The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.
  • Aedes aegypti has spread globally and is the primary vector of diseases such as dengue, Zika, chikungunya and yellow fever.
  • Deployments of the Friendly™ Aedes aegypti are planned to be conducted on Ebeye Island where, in 2019, a severe dengue outbreak forced a 'state of health emergency'.
  • Oxitec's CEO, Grey Frandsen, said, "We're honoured that our Friendly™ Aedes aegypti solution has been selected by the Ministry of Health of the Republic of the Marshall Islands for a groundbreaking new pilot program to address the invasive Aedes aegypti mosquito in the RMI.

Groundbreaking Partnership to Combat Dengue Mosquito in the Republic of the Marshall Islands Will Deploy Oxitec Friendly™ Aedes aegypti Solution

Retrieved on: 
Friday, March 31, 2023
RMI, Male, Partnership, Bee, Human services, Public, Yellow fever, Chikungunya, Centers for Disease Control and Prevention, Female, OXFORD, Government, Butterfly, CDC, Ministry, Notifiable disease, Republic, Fever Dream, Marshall Islands, Stockholm Environment Institute US Center, City, Ecosystem, United States Department of Health and Human Services, Vaccine, Zika fever, Pacific Ocean, Oxitec, Aedes, Ebeye Island

The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.

Key Points: 
  • The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.
  • Aedes aegypti has spread globally and is the primary vector of diseases such as dengue, Zika, chikungunya and yellow fever.
  • Deployments of the Friendly™ Aedes aegypti are planned to be conducted on Ebeye Island where, in 2019, a severe dengue outbreak forced a 'state of health emergency'.
  • Oxitec's CEO, Grey Frandsen, said, "We're honoured that our Friendly™ Aedes aegypti solution has been selected by the Ministry of Health of the Republic of the Marshall Islands for a groundbreaking new pilot program to address the invasive Aedes aegypti mosquito in the RMI.

AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development

Retrieved on: 
Friday, March 24, 2023
Vaccine, GSK, ITM, Tick-borne encephalitis, Civil service commission, HIV, Veterinary medicine, CEPI, COVID-19, Infection, University, Ebola, Yellow fever, Global health, Research, Shingles, Doctor of Philosophy, National Immunization Technical Advisory Group, Book, RSV, European Commission, MD, Influenza vaccine, Tropical medicine, UN, Travel medicine, Vertically transmitted infection, Rabies, WHO, Hygiene, Polyclinic, UNAIDS, London School of Hygiene and Tropical Medicine, Malaria, Management, Zoster vaccine, Global Health

Leuven, Belgium, 24 March 2023 – AstriVax has announced that Dr Emmanuel Hanon will chair the company’s scientific advisory board.

Key Points: 
  • Leuven, Belgium, 24 March 2023 – AstriVax has announced that Dr Emmanuel Hanon will chair the company’s scientific advisory board.
  • Renowned infectious disease experts Dr Peter Piot and Dr Patrick Soentjens have been appointed as the first scientific advisors to the AstriVax scientific advisory board that is being composed.
  • With the support of its scientific advisory board, AstriVax will continue to build its innovative plug-and-play vaccine platform to address important unmet needs in global health.
  • Their combined experience covers the full spectrum of infectious diseases, prophylactic and therapeutic vaccine development and global health management.

Climate change likely to turn New York into a breeding ground for dengue-carrying mosquitoes

Retrieved on: 
Tuesday, February 21, 2023
AE, Yellow fever, Infection, Climate change, Chikungunya, Clothing, BlueDot, World Health Organization, Urbanization, Aedes aegypti, Ecosystem, Temperature, Risk, Intelligence, City, Education, Notifiable disease, COVID-19, Fever Dream, Zika virus, Vaccine, Zika fever, Aedes

TORONTO, Feb. 21, 2023 /PRNewswire-PRWeb/ -- BlueDot Inc., a leading artificial and human intelligence organization for detecting, assessing, and responding to global infectious disease threats, announced today that its latest forecasting models reveal that climate change is causing a major expansion of areas where Aedes (Ae.) genus mosquitoes could breed and survive over the next 10 years. These mosquitoes are known carriers for chikungunya, dengue, yellow fever and Zika, which are four of the most disruptive mosquito-borne diseases.

Key Points: 
  • These mosquitoes are known carriers for chikungunya, dengue, yellow fever and Zika, which are four of the most disruptive mosquito-borne diseases.
  • Driven by factors like climate change, urbanization, and ecosystem disruption, mosquitoes have already begun to move beyond their traditional habitat and have been found in some of these regions**.
  • "We've never before seen mosquitoes appear within these territories, at a rate where local infection is possible."
  • aegypti mosquitoes under the projected climate over the next 10 years with five-by-five-kilometre granularity.